The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Bo Ahrén

Department of Clinical Sciences

Lund University


SE-221 84 Lund



Name/email consistency: high



  • Department of Clinical Sciences, Lund University, B11 BMC, SE-221 84 Lund, Sweden. 2001 - 2012
  • Department of Vascular Medicine, Malmö University Hospital and the Department of Medicine, Lund University, Sweden. 2006


  1. Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes. Farngren, J., Persson, M., Schweizer, A., Foley, J.E., Ahrén, B. J. Clin. Endocrinol. Metab. (2012) [Pubmed]
  2. Using albumin to improve the therapeutic properties of diabetes treatments. Ahrén, B., Burke, B. Diabetes. Obes. Metab (2012) [Pubmed]
  3. Incretin hormones and the up-regulation of insulin secretion in insulin resistance. Ahrén, B. J. Clin. Endocrinol. Metab. (2012) [Pubmed]
  4. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. Lindgren, O., Carr, R.D., Deacon, C.F., Holst, J.J., Pacini, G., Mari, A., Ahrén, B. J. Clin. Endocrinol. Metab. (2011) [Pubmed]
  5. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Ahrén, B., Foley, J.E., Bosi, E. Diabetes. Obes. Metab (2011) [Pubmed]
  6. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? Ahrén, B. Curr. Diab. Rep. (2011) [Pubmed]
  7. Reply to the letter by P. Guillausseau Regarding "Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yet Closed". Ahrén, B. Curr. Diab. Rep. (2011) [Pubmed]
  8. Study on administration of 1,5-anhydro-D-fructose in C57BL/6J mice challenged with high-fat diet. Mei, J., Yu, S., Ahrén, B. BMC. Endocr. Disord (2010) [Pubmed]
  9. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Ahrén, B., Foley, J.E., Ferrannini, E., Matthews, D.R., Zinman, B., Dejager, S., Fonseca, V.A. Diabetes. Care (2010) [Pubmed]
  10. Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Ahrén, B. Diabetes (2009) [Pubmed]
  11. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Ahrén, B. Nat. Rev. Drug. Discov (2009) [Pubmed]
  12. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. Ahrén, B., Schweizer, A., Dejager, S., Dunning, B.E., Nilsson, P.M., Persson, M., Foley, J.E. J. Clin. Endocrinol. Metab. (2009) [Pubmed]
  13. Effects of conjugated linoleic acid plus n-3 polyunsaturated fatty acids on insulin secretion and estimated insulin sensitivity in men. Ahrén, B., Mari, A., Fyfe, C.L., Tsofliou, F., Sneddon, A.A., Wahle, K.W., Winzell, M.S., Pacini, G., Williams, L.M. Eur. J. Clin. Nutr (2009) [Pubmed]
  14. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. Ahrén, B. Best Pract. Res. Clin. Endocrinol. Metab. (2009) [Pubmed]
  15. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Ahrén, B. Vasc. Health. Risk. Manag (2008) [Pubmed]
  16. Disturbed alpha-cell function in mice with beta-cell specific overexpression of human islet amyloid polypeptide. Ahrén, B., Sörhede Winzell, M. Exp. Diabetes. Res (2008) [Pubmed]
  17. Clinical measures of islet function: usefulness to characterize defects in diabetes. Ahrén, B., Pratley, R.E., Soubt, M., Dunning, B.E., Foley, J.E. Curr. Diabetes. Rev (2008) [Pubmed]
  18. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Ahrén, B., Foley, J.E. Int. J. Clin. Pract. Suppl (2008) [Pubmed]
  19. Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. Ahrén, B. Ann. N. Y. Acad. Sci. (2008) [Pubmed]
  20. Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans. Ahrén, B. Diabetologia (2008) [Pubmed]
  21. The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. Ahrén, B., Winzell, M.S., Pacini, G. J. Endocrinol. (2008) [Pubmed]
  22. DPP-4 inhibitors. Ahrén, B. Best Pract. Res. Clin. Endocrinol. Metab. (2007) [Pubmed]
  23. Insulin secretion and insulin sensitivity in relation to fasting glucose in healthy subjects. Ahrén, B. Diabetes. Care (2007) [Pubmed]
  24. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Ahrén, B. Curr. Diab. Rep. (2007) [Pubmed]
  25. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Ahrén, B., Winzell, M.S., Wierup, N., Sundler, F., Burkey, B., Hughes, T.E. Regul. Pept. (2007) [Pubmed]
  26. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Ahrén, B., Pacini, G., Tura, A., Foley, J.E., Schweizer, A. Horm. Metab. Res. (2007) [Pubmed]
  27. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Ahrén, B. Diabetes. Care (2007) [Pubmed]
  28. Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women. Lindgärde, F., Vessby, B., Ahrén, B. Am. J. Clin. Nutr. (2006) [Pubmed]
  29. Glucagon secretion in relation to insulin sensitivity in healthy subjects. Ahrén, B. Diabetologia (2006) [Pubmed]
  30. A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1alpha. Ahrén, B., Pacini, G. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006) [Pubmed]
  31. The insulin response to gastric glucose is reduced in PAC1 and GRP receptor gene deleted mice. Ahrén, B. Nutr. Metab. Cardiovasc. Dis (2006) [Pubmed]
  32. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Ahrén, B. Expert. Opin. Investig. Drugs (2006) [Pubmed]
  33. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Ahrén, B., Hughes, T.E. Endocrinology (2005) [Pubmed]
  34. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?. Ahrén, B. Diabetologia (2005) [Pubmed]
  35. Type 2 diabetes, insulin secretion and beta-cell mass. Ahrén, B. Curr. Mol. Med. (2005) [Pubmed]
  36. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Ahrén, B., Pacini, G., Foley, J.E., Schweizer, A. Diabetes. Care (2005) [Pubmed]
  37. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Ahrén, B., Thomaseth, K., Pacini, G. Diabetologia (2005) [Pubmed]
  38. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Ahrén, B., Sörhede Winzell, M., Burkey, B., Hughes, T.E. Eur. J. Pharmacol. (2005) [Pubmed]
  39. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Ahrén, B. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) [Pubmed]
  40. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Ahrén, B., Pacini, G. Eur. J. Endocrinol. (2004) [Pubmed]
  41. Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Ahrén, B., Pacini, G., Wynick, D., Wierup, N., Sundler, F. Endocrinology (2004) [Pubmed]
  42. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Ahrén, B., Gomis, R., Standl, E., Mills, D., Schweizer, A. Diabetes. Care (2004) [Pubmed]
  43. GLP-1 and extra-islet effects. Ahrén, B. Horm. Metab. Res. (2004) [Pubmed]
  44. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Ahrén, B., Schmitz, O. Horm. Metab. Res. (2004) [Pubmed]
  45. Increased insulin sensitivity is associated with reduced insulin and glucagon secretion and increased insulin clearance in man. Ahrén, B., Thorsson, O. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  46. Acylation stimulating protein stimulates insulin secretion. Ahrén, B., Havel, P.J., Pacini, G., Cianflone, K. Int. J. Obes. Relat. Metab. Disord. (2003) [Pubmed]
  47. Gut peptides and type 2 diabetes mellitus treatment. Ahrén, B. Curr. Diab. Rep. (2003) [Pubmed]
  48. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Ahrén, B., Holst, J.J., Mari, A. Diabetes. Care (2003) [Pubmed]
  49. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J.W., Dickinson, S., Holmes, D. Diabetes. Care (2002) [Pubmed]
  50. Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. Ahrén, B., Pacini, G. Am. J. Physiol. Endocrinol. Metab. (2002) [Pubmed]
  51. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Ahrén, B., Holst, J.J. Diabetes (2001) [Pubmed]
  52. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Ahrén, B., Larsson, H. Diabetologia (2001) [Pubmed]
WikiGenes - Universities